CAPTRUST Financial Advisors’s Provectus Biopharmaceuticals PVCT Stock Holding History
Bought
Maintained
Sold
Other funds holding PVCT
CAPTRUST Financial Advisors's PVCT Position: Q3 2022 in Review
CAPTRUST Financial Advisors sold out of Provectus Biopharmaceuticals (PVCT) in Q3 2022, closing a stake of 57,659 shares — an estimated $3K sold.
CAPTRUST Financial Advisors first reported a position in PVCT in Q2 2020 and held it in 8 quarters. The position peaked at $3K in Q2 2022. 7 funds tracked by Wall St. Rank hold PVCT as of Q3 2022.
- CAPTRUST Financial Advisors reported no remaining Provectus Biopharmaceuticals position as of Q3 2022 after selling out during the quarter.
- CAPTRUST Financial Advisors sold 57,659 Provectus Biopharmaceuticals shares in Q3 2022, an estimated $3K.
- CAPTRUST Financial Advisors first reported a position in Provectus Biopharmaceuticals in Q2 2020 and held it in 8 quarters.
- CAPTRUST Financial Advisors's Provectus Biopharmaceuticals position peaked at $3K in Q2 2022.
- 7 funds tracked by Wall St. Rank held Provectus Biopharmaceuticals as of Q3 2022.
Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.